Kovaxin, developed by the Indian Council of Medical Research and Bharat Biotech, is being tested at 12 institutes across India. This indigenous vaccine is one of the frontrunners in the race for coronovirus vaccine in the country.
The Hyderabad-based firm stated, “Bharat Biotech proudly announces animal study results of covaxin — these results demonstrate protective efficacy in a live viral challenge model.”
The drugmaker said: “The vaccine candidate was found to produce a strong immune response. Thus, preventing the infection and disease of the primate in high amounts to survive the SARS-Cove-2 virus.”
Coronavirus epidemic live update
During the procedure, a two-dose vaccination regime of inactive SARS-CoV-2 vaccine candidates was administered in 20 rhesus macas, which were divided into four groups.
One group was administered with a placebo, while three groups were immunized with three different vaccine candidates at zero and 14 days. All maca were exposed to viral challenge 14 days after the second dose.
Bharat Biotech stated, “The results showed a protective effect, increasing SARS-COV-2 specific IgG and neutralizing antibodies, reducing virus replication in the nasal cavity, throat, and lung tissue of monkeys.”
Unlike the placebo group, no evidence of pneumonia was seen by histopathological examination in the vaccinated groups. Animal adverse events were not observed in immunized animals with two-dose vaccination.
In the video: Animal testing of covaxin elicits strong immune response, says Bharat Biotech